You are here

Article Text

Article menu
Download PDFPDF
Clinical pharmacy
CP-229 Is there an added value contribution of biological glue in surgery of cyanotic congenital heart diseases?
  1. A Cheikh1,
  2. MR Ajaja2,
  3. MA El Wartiti3,
  4. M Bouatia4,
  5. A Bennana5,
  6. Y Cherrah6,
  7. R Razine7,
  8. A Slaoui2,
  9. A El Hassani8,
  10. Y Chikhaoui9
  1. 1Abulcasis University — Cheikh Zaid Hospital, Rabat, Morocco
  2. 2Abulcasis University — Cheikh Zaid Hospital, Cardiac Surgery, Rabat, Morocco
  3. 3Faculty of Medicine and Pharmacy — Clinical Pharmacy, Mohammed v Military Teaching Hospital, Rabat, Morocco
  4. 4Mohammed v University — Faculty of Medicine and Pharmacy, Pediatric Hospital, Rabat, Morocco
  5. 5Mohammed v University — Faculty of Medicine and Pharmacy, Mohammed v Military Teaching Hospital, Rabat, Morocco
  6. 6Mohammed v University — Faculty of Medicine and Pharmacy, Pharmacology and Toxicology, Rabat, Morocco
  7. 7Mohammed v University — Faculty of Medicine and Pharmacy, Public Health, Rabat, Morocco
  8. 8Mohammed v University — Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital, Rabat, Morocco
  9. 9Mohammed v University — Faculty of Medicine and Pharmacy, Cheikh Zaid Hospital-Cardiac Surgery, Rabat, Morocco

Abstract

Background Biological glues are indicated in surgery to improve haemostasis when conventional techniques such as compression, sutures or electrocoagulation are insufficient. Indications for biological glues are reducing bleeding occurring after surgery, including particular contexts.

Purpose Through this work, we evaluated the impact of using biological glue in surgical procedures for cyanotic congenital heart diseases on the cost of pharmaceuticals, postoperative intensive care, volume of postoperative bleeding and number of bags of blood and blood derivatives transfused.

Material and methods A study of patient records who underwent surgery to treat a cyanotic congenital heart disease (tetralogy of Fallot, pulmonary atresia, transposition of the great arteries) was made between 2010 and 2014. All patients in whom the surgeon used biological glue were followed since the introduction of the glue to the hospital in 2012.

Other patient records were randomly selected; they represent those treated by surgery for their cyanotic congenital heart diseases before the introduction of the biological glue to the hospital. A Mann-Whitney analysis was used to define differences between the two groups of patients. Statistical analysis was performed using SPSS V.13.0.

Results 60 patient records were collected; the surgeon has used biological glue in 28 patients after the introduction of this product to the hospital.

View this table:
Abstract CP-229 Table 1

Conclusion Bleeding is an important factor for morbidity and mortality in surgical procedures. Bleeding can have serious consequences for patients at a young age, especially for cyanotic congenital heart diseases. The contribution of biological glue is already confirmed in intraoperative haemostasis. However, our results show that in our studied series, the use of the biological glue did not reduce the postoperative bleeding volume, did not reduce hospital stay in the ICU and did not reduce the number of bags of blood and blood derivatives transfused. These results should be confronted by other results from other series.

References and/or Acknowledgements Cardiac surgery team.

No conflict of interest.

https://doi.org/10.1136/ejhpharm-2016-000875.229

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.